Your browser is no longer supported. Please, upgrade your browser.
BiomX Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own2.40% Shs Outstand27.08M Perf Week1.27%
Market Cap47.21M Forward P/E- EPS next Y- Insider Trans9.61% Shs Float22.84M Perf Month-1.85%
Income-34.90M PEG- EPS next Q- Inst Own24.40% Short Float0.13% Perf Quarter-34.57%
Sales- P/S- EPS this Y64.40% Inst Trans- Short Ratio0.33 Perf Half Y-65.44%
Book/sh1.97 P/B0.81 EPS next Y- ROA-49.70% Target Price12.50 Perf Year-76.30%
Cash/sh- P/C- EPS next 5Y- ROE-65.40% 52W Range1.42 - 9.05 Perf YTD-0.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-82.43% Beta-
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low11.97% ATR0.15
Employees95 Current Ratio7.80 Sales Q/Q- Oper. Margin- RSI (14)44.70 Volatility11.70% 8.62%
OptionableNo Debt/Eq0.27 EPS Q/Q2.90% Profit Margin- Rel Volume0.43 Prev Close1.65
ShortableYes LT Debt/Eq0.27 EarningsNov 15 BMO Payout- Avg Volume92.85K Price1.59
Recom- SMA201.39% SMA50-13.17% SMA200-60.05% Volume39,962 Change-3.64%
Apr-15-21Initiated Ladenburg Thalmann Buy $25
Jan-04-22 07:00AM  
Nov-17-21 08:00AM  
Nov-15-21 06:00AM  
Nov-09-21 08:00AM  
Oct-25-21 10:00AM  
Oct-18-21 07:00AM  
Oct-13-21 07:00AM  
Sep-02-21 04:05PM  
Aug-16-21 06:30AM  
Aug-12-21 08:00AM  
Jul-26-21 08:13AM  
Jun-14-21 06:30AM  
Jun-09-21 06:30AM  
May-25-21 10:46AM  
May-24-21 06:30AM  
May-18-21 08:00AM  
Apr-20-21 07:00AM  
Mar-31-21 06:30AM  
Mar-24-21 06:30AM  
Mar-02-21 07:00AM  
Mar-01-21 07:00AM  
Feb-02-21 06:30AM  
Jan-04-21 06:30AM  
Dec-09-20 04:30PM  
Dec-02-20 06:21PM  
Nov-16-20 06:30AM  
Nov-12-20 06:30AM  
Nov-10-20 04:30PM  
Nov-05-20 06:30AM  
Nov-04-20 06:30AM  
Oct-21-20 06:30AM  
Oct-05-20 06:30AM  
Sep-10-20 04:30PM  
Sep-02-20 06:30AM  
Aug-13-20 06:30AM  
Aug-12-20 12:17PM  
Aug-06-20 07:00AM  
May-14-20 06:30AM  
May-11-20 05:00PM  
Apr-07-20 04:05PM  
Mar-31-20 06:30AM  
Mar-26-20 06:30AM  
Mar-20-20 08:00AM  
Feb-17-20 07:00AM  
Dec-02-19 07:30AM  
Nov-12-19 07:30AM  
Nov-04-19 05:38PM  
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolfson MarinaSVP of Finance & OperationsJul 28Buy4.003,75015,0003,750Jul 30 09:55 AM
Sullivan Lynne MarieDirectorJul 28Buy4.0012,50050,00012,500Jul 30 09:53 AM
Solomon Jonathan EitanChief Executive OfficerJul 28Buy4.0025,000100,00025,000Jul 30 09:52 AM
Greig RussellDirectorJul 28Buy4.003,75015,0003,750Jul 30 09:50 AM
SEKHRI PAUL JDirectorJul 28Buy4.0012,50050,00012,500Jul 30 09:49 AM
Moses Alan CharlesDirectorJul 28Buy4.005,00020,0005,000Jul 30 09:48 AM